Good morning traders, Let's get right to it. The timing looks perfect here. The chart is sitting just over the 50 day with an RSI of 44. http://stockcharts.com/h-sc/ui?s=xxii 22nd Century Group, Inc. (NYSE-MKT: XXII) is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking. XXII owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. In late December 2015 (NYSE: XXII) submitted an application for a Modified Risk Tobacco Product (MRTP) - more notably their proprietary Very Low Nicotine (VLN) products. In early January 2016, (NYSE: XXII) was contacted by the FDA requesting a meeting. In Mid January (NYSE: XXII) met with the FDA - 42 people attended on behalf of the FDA. Such a quick response shows how serious the FDA is about this issue. There is considerable third party published data on the benefits of reducing the exposure to nicotine and it is in the interest of the general health of the nation! In late April, Health Canada made a statement that they are looking into forcing tobacco companies into making smoking less addictive. See the two articles below. Quote from health Canada: ".....reducing the nicotine level of cigarettes is the most-discussed means of lessening their addictiveness...." Health Canada articles: http://www.techtimes.com/articles/152264/20160421/health-canada-mulls-forcing-tobacco-companies-to-make-cigarettes-less-addictive.htm http://news.nationalpost.com/news/canada/health-canada-looks-at-forcing-tobacco-companies-to-make-cigarettes-less-addictive The CEO of $152B market Cap, Philip Morris CEO is now talking about "reduced risk" ....(NYSE: XXII) holds the patents to help them get there! http://www.reuters.com/article/britain-tobacco-idUSL5N18G3CB Philip Morris said it would keep trying to "focus on efforts to develop and commercialize scientifically substantiated reduced-risk products". CNBC recent Interview http://www.cnbc.com/2015/05/07/philip-morris-aims-for-reduced-risk-products.html Recent price target of $4.50 issued by Chardan- Talks about substantial value in Cannabinoid research as well. - http://broadstreetalerts.com/wp-content/uploads/2016/05/XXII_2016-05-16-Chardan-1.pdf This should get everyone started, we will be back with an updated report. The Team |
|